AUTHOR=Knight Daniel B. , Rudin Susan D. , Bonomo Robert A. , Rather Philip N. 

TITLE=Acinetobacter nosocomialis: Defining the Role of Efflux Pumps in Resistance to Antimicrobial Therapy, Surface Motility, and Biofilm Formation

JOURNAL=Frontiers in Microbiology

VOLUME=9

YEAR=2018

URL=https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2018.01902

DOI=10.3389/fmicb.2018.01902

ISSN=1664-302X

ABSTRACT=<p><italic>Acinetobacter nosocomialis</italic> is a member of the <italic>Acinetobacter calcoaceticus-Acinetobacter baumannii</italic> (ACB) complex. Increasingly, reports are emerging of the pathogenic profile and multidrug resistance (MDR) phenotype of this species. To define novel therapies to overcome resistance, we queried the role of the major efflux pumps in <italic>A. nosocomialis</italic> strain M2 on antimicrobial susceptibility profiles. <italic>A. nosocomialis</italic> strains with the following mutations were engineered by allelic replacement; Δ<italic>adeB</italic>, Δ<italic>adeJ</italic>, and Δ<italic>adeB/adeJ</italic>. In these isogenic strains, we show that the Δ<italic>adeJ</italic> mutation increased susceptibility to beta-lactams, beta-lactam/beta-lactamase inhibitors, chloramphenicol, monobactam, tigecycline, and trimethoprim. The Δ<italic>adeB</italic> mutation had a minor effect on resistance to certain beta-lactams, rifampicin and tigecycline. In addition, the Δ<italic>adeJ</italic> mutation resulted in a significant decrease in surface motility and a minor decrease in biofilm formation. Our results indicate that the efflux pump, AdeIJK, has additional roles outside of antibiotic resistance in <italic>A. nosocomialis</italic>.</p>